Associate Professor Stavros Selemidis is a research intensive academic staff member and his research and teaching are aligned with 3 of RMIT's strategic goals including: [Goal 5] "Research and innovation: creating impact through collaboration"; [Goal 6] "Industry and enterprise embedded in everything we do" and [Goal 7] "Global reach and outlook".
A/Prof Selemidis is the leader of the RMIT Oxidant and Inflammation Biology Group (OXIB), an integral part of the Chronic Infectious Inflammatory Diseases (CIID) Research Program and we are focussed on global health burden of respiratory viral disease and cancer that afflict mankind and livestock industries.
Since joining RMIT in Feb 2017, Stavros has been a founding executive member of the leadership team of the CIID Program within the SHBS and has significantly expanded CIIDs research, training and mentoring capacities. At RMIT, A/Prof Selemidis established, manages and supervises a multi-cultural, gender-balanced research team of 14 including 2 post-doctoral scientists (including a VC RMIT fellow), 1 research assistant, 4 PhD, 2 BBiomedSci honours and 4 WIL students. This complements his established RMIT-, Australia- and international-wide coalition of scientists, clinicians and industry that facilitate OXIB's cutting edge research. Selemidis has developed and implements a staff mentoring program called "The Career Facilitation Program". He is a member of SEH OHS and of RMIT's animal ethics committees. Selemidis has made senior contributions to national/international government agencies including NHMRC, ARC and MRC UK. Selemidis reviews for high impact journals including Nature Reviews Cancer and Nature Communications. A/Prof Selemidis has delivered 14 international and 36 national invited talks, including the prestigious Gordon conference.
In 18 months at RMIT, Stavros has published a Nature Communications paper as senior author; had global media attention and filed an International Patent Application on novel anti-viral therapeutics with a strategy over the next 2 years to obtain funding for this work with industry links. Stavros has 48 peer reviewed publications of high impact (All Q1) including Nature Reviews Drug Discovery (IF 57.1); Nature Communications (IF 12.4). 8 publications are citation classics (>100 citations) and 1 has >650 citations. Sustained competitive national/international Category 1 and 2 research funding including NHMRC and ARC Fellowships and NHMRC Project Grants totalling $7.6M ($2.93M from industry). Selemidis has had 4 PhD completions; 13 Hons students (all received H1).
In summary, A/Prof Selemidis' activities in engagement and research have established an internationally recognised and competitive respiratory and cancer research group which has increased RMIT's research capacity and expanded the SHBS's priority research area of chronic diseases management.
- Martini, C.,Logan, J.,Sorvina, A.,Gordon, C.,Selemidis, S., et al, . (2023). Aberrant protein expression of Appl1, Sortilin and Syndecan-1 during the biological progression of prostate cancer In: Pathology, 55, 40 - 51
- Chan, S.,Brassington, K.,Almerdasi, S.,Dobric, A.,De Luca, S.,Coward-Smith, M.,Wang, H.,Mou, K.,Akhtar, A.,Alateeq, R.,Wang, W.,Seow, H.,Selemidis, S.,Bozinovski, S.,Vlahos, R. (2023). Inhibition of oxidative stress by apocynin attenuated chronic obstructive pulmonary disease progression and vascular injury by cigarette smoke exposure In: British Journal of Pharmacology, , 1 - 17
- Ffrench, B.,Kashdan, E.,Huang, Y.,Spillane, C.,Selemidis, S., et al, . (2023). CTC-5: A novel digital pathology approach to characterise circulating tumour cell biodiversity In: Heliyon, 9, 1 - 10
- Mohamed, B.,Ward, M.,Bates, M.,Selemidis, S., et al, . (2023). Ex vivo expansion of circulating tumour cells (CTCs) In: Scientific Reports, 13, 1 - 13
- Logan, J.,Hopkins, A.,Martini, C.,Sorvina, A.,Selemidis, S., et al, . (2023). Prediction of Prostate Cancer Biochemical and Clinical Recurrence Is Improved by IHC-Assisted Grading Using Appl1, Sortilin and Syndecan-1 In: Cancers, 15, 1 - 12
- Hossain, M.,Praveen, P.,Noorzi, N.,Wu, H.,Harrison, I.,Handley, T.,Selemidis, S.,Samuel, C.,Bathgate, R. (2023). Development of Novel High-Affinity Antagonists for the Relaxin Family Peptide Receptor 1 In: ACS Pharmacology and Translational Science, 6, 842 - 853
- Bates, M.,Mohamed, B.,Ward, M.,Selemidis, S., et al, . (2023). Circulating tumour cells: The Good, the Bad and the Ugly In: Biochimica et Biophysica Acta - Reviews on Cancer, 1878, 1 - 12
- Liong, S.,Miles, M.,Mohsenipour, M.,Liong, F.,Hill, E.,Selemidis, S. (2023). Influenza A virus infection during pregnancy causes immunological changes in gut-associated lymphoid tissues of offspring mice In: American journal of physiology. Gastrointestinal and liver physiology, 325, 230 - 238
- Oseghale, S.,Liong, S.,Coward-Smith, M.,To, E.,Erlich, J.,Selemidis, S.,Liong, F.,Miles, M.,Norouzi, S.,Vlahos, R.,Bozinovski, S., et al, . (2022). Influenza A virus elicits peri-vascular adipose tissue inflammation and vascular dysfunction of the aorta in pregnant mice In: PLoS Pathogens, 18, 1 - 21
- Lazniewska, J.,Bader, C.,Hickey, S.,Selemidis, S.,O'Leary, J.,Simpson, P.,Stagni, S.,Plush, S.,Massimiliano Massi, M.,Brooks, D. (2022). Rhenium(I) conjugates as tools for tracking cholesterol in cells In: Metallomics, 14, 1 - 15
3 PhD Completions6 PhD Current Supervisions
- A therapeutic solution for respiratory RNA viruses that corrects the patient’s TLR7-dependent inflammatory response. Funded by: NHMRC-Ideas Grants from (2023 to 2026)
- Influenza A viral infection and pregnancy complications. Funded by: NHMRC - Ideas Grants 2020 from (2021 to 2024)
- Development and validation of Random Positioning Machines for organoid tissue development of disease pathogenesis. Funded by: University of South Australia CAT0 from (2020 to 2021)
- Targeting endosomal NOX2 oxidase in viral disease. Funded by: 044-National Health and Medical Research Council (NHMRC) Project Grants 2017 from (2017 to 2020)
- Endosomal reactive oxygen species in tumour angiogenesis. Funded by: National Health and Medical Research Council (NHMRC) Project Grants 2016 from (2017 to 2022)